CN1232507C - 生长激素促分泌剂 - Google Patents

生长激素促分泌剂 Download PDF

Info

Publication number
CN1232507C
CN1232507C CNB018104916A CN01810491A CN1232507C CN 1232507 C CN1232507 C CN 1232507C CN B018104916 A CNB018104916 A CN B018104916A CN 01810491 A CN01810491 A CN 01810491A CN 1232507 C CN1232507 C CN 1232507C
Authority
CN
China
Prior art keywords
trp
gtrp
aib
boc
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018104916A
Other languages
English (en)
Chinese (zh)
Other versions
CN1431998A (zh
Inventor
让·马丁内斯
让－阿兰·费伦茨
文森特·格拉韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Eitner Had Taris LLC
Original Assignee
Aeterna Zentaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris GmbH filed Critical Aeterna Zentaris GmbH
Publication of CN1431998A publication Critical patent/CN1431998A/zh
Application granted granted Critical
Publication of CN1232507C publication Critical patent/CN1232507C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CNB018104916A 2000-06-13 2001-06-13 生长激素促分泌剂 Expired - Lifetime CN1232507C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21132600P 2000-06-13 2000-06-13
US60/211,326 2000-06-13
US23492800P 2000-09-26 2000-09-26
US60/234,928 2000-09-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200510084807 Division CN1736985A (zh) 2000-06-13 2001-06-13 生长激素促分泌剂

Publications (2)

Publication Number Publication Date
CN1431998A CN1431998A (zh) 2003-07-23
CN1232507C true CN1232507C (zh) 2005-12-21

Family

ID=26906052

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018104916A Expired - Lifetime CN1232507C (zh) 2000-06-13 2001-06-13 生长激素促分泌剂

Country Status (29)

Country Link
US (2) US6861409B2 (enExample)
EP (1) EP1289951B1 (enExample)
JP (2) JP3522265B2 (enExample)
KR (1) KR100825109B1 (enExample)
CN (1) CN1232507C (enExample)
AR (1) AR029941A1 (enExample)
AT (3) ATE302181T1 (enExample)
AU (2) AU2001266066B2 (enExample)
BG (3) BG66130B1 (enExample)
BR (1) BRPI0111591B8 (enExample)
CA (1) CA2407659C (enExample)
CY (2) CY1107710T1 (enExample)
CZ (2) CZ303173B6 (enExample)
DE (3) DE60130025T2 (enExample)
DK (3) DK1524272T3 (enExample)
ES (3) ES2288724T3 (enExample)
FR (1) FR19C1044I2 (enExample)
HU (1) HU229233B1 (enExample)
IL (2) IL153067A0 (enExample)
MX (1) MXPA02011899A (enExample)
NL (1) NL300999I2 (enExample)
NO (1) NO323873B1 (enExample)
NZ (1) NZ522280A (enExample)
PL (1) PL216676B1 (enExample)
PT (2) PT1524272E (enExample)
RU (1) RU2270198C2 (enExample)
SK (1) SK287169B6 (enExample)
TW (2) TWI305529B (enExample)
WO (1) WO2001096300A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407659C (en) * 2000-06-13 2010-11-09 Zentaris Ag Growth hormone secretagogues
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7034050B2 (en) * 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
EP1919492B1 (en) * 2005-07-22 2013-03-06 Ipsen Pharma Growth hormone secretagogues
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0603295D0 (en) * 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
US8431642B2 (en) * 2008-06-09 2013-04-30 Exxonmobil Chemical Patents Inc. Polyolefin adhesive compositions and articles made therefrom
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US10300101B2 (en) 2012-09-19 2019-05-28 Quality IP Holdings, LLC Methods and compositions for enhancing or maintaining fertility
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747922B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods and compositions for increasing sex steroids and growth hormones
US10292957B2 (en) 2012-09-20 2019-05-21 Quality IP Holdings, LLC Compositions and methods for treating fibromyalgia
US8747923B2 (en) 2012-09-20 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in canines
US8715752B2 (en) 2012-09-20 2014-05-06 Quality Ip Holdings, Inc. Compositions for increasing human growth hormone levels
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
US20150265680A1 (en) 2012-10-24 2015-09-24 Daiichi Sankyo Company, Limited Therapeutic agent for amyotrophic lateral sclerosis
CN105330720A (zh) * 2014-06-06 2016-02-17 深圳翰宇药业股份有限公司 一种制备马昔瑞林的方法
HUE057831T2 (hu) * 2015-09-21 2022-06-28 Lumos Pharma Inc Növekedési hormon hiányának felismerése és kezelése
US10894072B2 (en) 2017-02-13 2021-01-19 IP Quality Holdings, LLC Compositions and methods for treating fibromyalgia
US10288629B1 (en) 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
CN120294343A (zh) 2020-07-22 2025-07-11 阿特纳赞塔里斯有限公司 一种通过使用马昔瑞林诊断儿科患者中生长激素缺乏症的筛选方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
ATE122357T1 (de) * 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0730578A4 (en) * 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING INDOLYL GROUPS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONES
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
CA2407659C (en) * 2000-06-13 2010-11-09 Zentaris Ag Growth hormone secretagogues

Also Published As

Publication number Publication date
BRPI0111591B8 (pt) 2021-05-25
DE60130025D1 (de) 2007-09-27
BR0111591B1 (pt) 2014-02-04
DK1344773T3 (da) 2007-12-27
WO2001096300A1 (en) 2001-12-20
PL363081A1 (en) 2004-11-15
JP4932132B2 (ja) 2012-05-16
NO20025893D0 (no) 2002-12-09
HU229233B1 (en) 2013-09-30
HK1054224A1 (en) 2003-11-21
ATE370119T1 (de) 2007-09-15
SK17562002A3 (sk) 2003-05-02
AU6606601A (en) 2001-12-24
MXPA02011899A (es) 2003-04-22
NO20025893L (no) 2003-02-10
AU2001266066B2 (en) 2005-06-30
EP1289951B1 (en) 2005-08-17
KR20030007889A (ko) 2003-01-23
AR029941A1 (es) 2003-07-23
BG66216B1 (bg) 2012-05-31
DE60112753T2 (de) 2006-06-29
ATE302181T1 (de) 2005-09-15
JP2004503536A (ja) 2004-02-05
HUP0302026A2 (hu) 2003-09-29
CY1107710T1 (el) 2013-04-18
PT1344773E (pt) 2007-11-27
US20040229823A1 (en) 2004-11-18
ES2288724T3 (es) 2008-01-16
PT1524272E (pt) 2007-07-25
BG110771A (bg) 2011-03-31
ATE362472T1 (de) 2007-06-15
NL300999I1 (nl) 2019-07-17
DK1524272T3 (da) 2007-09-03
US7297681B2 (en) 2007-11-20
RU2270198C2 (ru) 2006-02-20
CN1431998A (zh) 2003-07-23
CZ305279B6 (cs) 2015-07-15
JP3522265B2 (ja) 2004-04-26
DE60128494D1 (de) 2007-06-28
CZ20024095A3 (cs) 2003-05-14
ES2250416T3 (es) 2006-04-16
SK287169B6 (sk) 2010-02-08
HUP0302026A3 (en) 2009-01-28
EP1289951A1 (en) 2003-03-12
DE60128494T2 (de) 2008-01-17
FR19C1044I2 (fr) 2020-07-24
DE60112753D1 (de) 2005-09-22
BR0111591A (pt) 2003-05-06
CY1107793T1 (el) 2013-06-19
PL216676B1 (pl) 2014-05-30
DK1289951T3 (da) 2005-12-19
CA2407659A1 (en) 2001-12-20
ES2292900T3 (es) 2008-03-16
TWI305529B (en) 2009-01-21
NL300999I2 (nl) 2019-08-28
TW200831076A (en) 2008-08-01
NO323873B1 (no) 2007-07-16
NZ522280A (en) 2004-09-24
JP2003335752A (ja) 2003-11-28
US6861409B2 (en) 2005-03-01
DE60130025T2 (de) 2008-05-15
BG107379A (bg) 2003-09-30
KR100825109B1 (ko) 2008-04-25
BG66130B1 (bg) 2011-06-30
BG66217B1 (bg) 2012-05-31
CZ303173B6 (cs) 2012-05-16
FR19C1044I1 (enExample) 2019-09-08
BG110708A (en) 2010-12-30
US20020165343A1 (en) 2002-11-07
IL153067A (en) 2010-05-31
CA2407659C (en) 2010-11-09
IL153067A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
CN1232507C (zh) 生长激素促分泌剂
CN1113895C (zh) 生长激素促分泌素
CN1088706C (zh) 新型杂环酰胺化合物及其医药用途
CN1052731C (zh) 具有生长激素释放特性的化合物
CN1111529C (zh) 作为神经激肽拮抗剂的哌嗪子基衍生物
CN1142911C (zh) 具有释放生长激素特性的化合物
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1469871A (zh) 作为生长激素促分泌素的取代的二肽
CN1208413A (zh) 促性腺激素释放激素拮抗剂
CN1152049C (zh) 用生长激素促分泌素治疗胰岛素抗性
CN1174504A (zh) 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
CN1409703A (zh) 4－氨基哌啶衍生物和它们作为药物的用途
CN1232462A (zh) 毒蕈碱拮抗剂
CN1208412A (zh) 促性腺激素释放激素拮抗剂
CN1143647A (zh) 促进生长激素释放的二肽
CN1092071A (zh) 促进生长激素释放的螺哌啶类化合物和同系物
CN1633297A (zh) 作为黑皮质素－4受体激动剂的酰化哌啶衍生物
CN1353701A (zh) 用作类胰蛋白酶抑制剂的肽基杂环酮类化合物
CN101068828A (zh) 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
CN1800186A (zh) 腺苷A2a受体拮抗剂
CN1344160A (zh) 用作生长激素促分泌剂的杂环芳族化合物
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1132511A (zh) 基质金属蛋白酶抑制剂
CN1097192A (zh) 逆转录酶病毒蛋白酶抑制剂
CN1179972C (zh) 促生长激素分泌剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: AYI TENA CENGTA LISI CO., LTD.

Free format text: FORMER NAME: ZENTARIS AG

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany, USA

Patentee after: A Eitner had Taris limited liability company

Address before: Frankfurt, Germany, USA

Patentee before: Zentaris GmbH

CX01 Expiry of patent term

Granted publication date: 20051221

CX01 Expiry of patent term